BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-85. [PMID: 16831079 DOI: 10.1586/14737140.6.7.1075] [Cited by in Crossref: 239] [Cited by in F6Publishing: 231] [Article Influence: 14.9] [Reference Citation Analysis]
Number Citing Articles
1 Yuan J, Liu Y, Zhang Q, Ren Z, Li G, Tian R. CircPRDM2 Contributes to Doxorubicin Resistance of Osteosarcoma by Elevating EZH2 via Sponging miR-760. Cancer Manag Res 2021;13:4433-45. [PMID: 34103997 DOI: 10.2147/CMAR.S295147] [Reference Citation Analysis]
2 Wang K, Zhuang Y, Liu C, Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K–Akt signaling. Archives of Biochemistry and Biophysics 2012;526:38-43. [DOI: 10.1016/j.abb.2012.07.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
3 Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA, Rebbaa A. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 2009;296:C65-74. [PMID: 18971393 DOI: 10.1152/ajpcell.00082.2008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
4 Yang F, Nam S, Zhao R, Tian Y, Liu L, Horne DA, Jove R. A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling. Cancer Biol Ther 2013;14:1024-31. [PMID: 24025361 DOI: 10.4161/cbt.26045] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
5 Das B, Jain N, Mallick B. piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair. Commun Biol 2021;4:1312. [PMID: 34799689 DOI: 10.1038/s42003-021-02844-1] [Reference Citation Analysis]
6 Kun-peng Z, Xiao-long M, Lei Z, Chun-lin Z, Jian-ping H, Tai-cheng Z. Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics 2018;10:1327-46. [DOI: 10.2217/epi-2018-0023] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
7 Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett 2017;409:66-80. [PMID: 28888998 DOI: 10.1016/j.canlet.2017.08.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
8 Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, D’Anneo A, Carlisi D, De Blasio A, Giuliano M, Tesoriere G. MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 2014;45:2013-2023. [PMID: 25174983 DOI: 10.3892/ijo.2014.2618] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
9 Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R, Reed D. Advances in therapy for pediatric sarcomas. Curr Oncol Rep. 2014;16:395. [PMID: 24894064 DOI: 10.1007/s11912-014-0395-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
10 Fordham AM, Ekert PG, Fleuren EDG. Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas. Biochim Biophys Acta Rev Cancer 2021;:188613. [PMID: 34390800 DOI: 10.1016/j.bbcan.2021.188613] [Reference Citation Analysis]
11 Zhu XZ, Yin HM, Mei J. Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy. Acta Pharmacol Sin 2010;31:970-6. [PMID: 20686521 DOI: 10.1038/aps.2010.97] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Zhang L, Lyer AK, Yang X, Kobayashi E, Guo Y, Mankin H, Hornicek FJ, Amiji MM, Duan Z. Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. Int J Nanomedicine 2015;10:2913-24. [PMID: 25931818 DOI: 10.2147/IJN.S79143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
13 Suenaga N, Kuramitsu M, Komure K, Kanemaru A, Takano K, Ozeki K, Nishimura Y, Yoshida R, Nakayama H, Shinriki S, Saito H, Jono H. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma. Int J Mol Sci 2019;20:E5194. [PMID: 31635163 DOI: 10.3390/ijms20205194] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
14 Hameed M, Dorfman H. Primary malignant bone tumors--recent developments. Semin Diagn Pathol 2011;28:86-101. [PMID: 21675380 DOI: 10.1053/j.semdp.2011.02.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
15 Feng W, Wang Z, Feng D, Zhu Y, Zhang K, Huang W. The effects of common variants in MDM2 and GNRH2 genes on the risk and survival of osteosarcoma in Han populations from Northwest China. Sci Rep 2020;10:15939. [PMID: 32994424 DOI: 10.1038/s41598-020-72995-4] [Reference Citation Analysis]
16 Zhang Z, Zhao M, Wang G. Upregulation of microRNA-7 contributes to inhibition of the growth and metastasis of osteosarcoma cells through the inhibition of IGF1R. J Cell Physiol 2019;234:22195-206. [PMID: 31102265 DOI: 10.1002/jcp.28787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, Avondo S, Sessa G. Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Front Pharmacol 2017;8:150. [PMID: 28439237 DOI: 10.3389/fphar.2017.00150] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
18 Li X, Yan ML, Yu Q. Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method. Oncol Lett 2017;13:4378-84. [PMID: 28599440 DOI: 10.3892/ol.2017.5953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
19 Chen R, Huang LH, Gao YY, Yang JZ, Wang Y. Identification of differentially expressed genes in MG63 osteosarcoma cells with drug‑resistance by microarray analysis. Mol Med Rep 2019;19:1571-80. [PMID: 30569145 DOI: 10.3892/mmr.2018.9774] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
20 Chen MW, Wu XJ. SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway. Technol Cancer Res Treat 2018;17:1533033818811143. [PMID: 30482097 DOI: 10.1177/1533033818811143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Jin W, Zhou L, Yan B, Yan L, Liu F, Tong P, Yu W, Dong X, Xie L, Zhang J, Xu Y, Li C, Yuan Q, Shan L, Efferth T. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway. J Cell Mol Med 2018;22:4423-36. [PMID: 29993186 DOI: 10.1111/jcmm.13742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
22 Tan B, Xu X, Zhang Q, Yuan Z, Dong J. The tumor suppressive role of TIMP3 in the human osteosarcoma cells. J Orthop Sci 2021:S0949-2658(21)00077-4. [PMID: 33814198 DOI: 10.1016/j.jos.2021.02.004] [Reference Citation Analysis]
23 Fan J, Yang X, Bi Z. 6-Gingerol inhibits osteosarcoma cell proliferation through apoptosis and AMPK activation. Tumor Biol 2015;36:1135-41. [DOI: 10.1007/s13277-014-2723-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
24 Tang H, Tang Z, Jiang Y, Wei W, Lu J. Pathological and therapeutic aspects of matrix metalloproteinases: Implications in osteosarcoma. Asia Pac J Clin Oncol 2019;15:218-24. [PMID: 31111666 DOI: 10.1111/ajco.13165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Jeon DG, Song WS. How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther 2010;10:1313-25. [PMID: 20735316 DOI: 10.1586/era.10.79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
26 Avnet S, Lemma S, Cortini M, Pellegrini P, Perut F, Zini N, Kusuzaki K, Chano T, Grisendi G, Dominici M, De Milito A, Baldini N. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance. Oncotarget 2016;7:63408-23. [PMID: 27566564 DOI: 10.18632/oncotarget.11503] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
27 Li Y, Xian M, Yang B, Ying M, He Q. Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells. Stem Cell Reports. 2017;8:1617-1629. [PMID: 28552603 DOI: 10.1016/j.stemcr.2017.04.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
28 Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer 2014;110:2896-904. [PMID: 24853187 DOI: 10.1038/bjc.2014.254] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
29 Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA. Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene. PLoS One 2016;11:e0163859. [PMID: 27685995 DOI: 10.1371/journal.pone.0163859] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
30 Xu W, Li Z, Zhu X, Xu R, Xu Y. miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma. Med Sci Monit 2018;24:8812-21. [PMID: 30518744 DOI: 10.12659/MSM.911972] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
31 Ji Y, Liu J, Zhu W, Ji J. circ_0002060 Enhances Doxorubicin Resistance in Osteosarcoma by Regulating the miR-198/ABCB1 Axis. Cancer Biother Radiopharm 2020. [PMID: 33351694 DOI: 10.1089/cbr.2020.4240] [Reference Citation Analysis]
32 Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009;8:2122-30. [PMID: 19638450 DOI: 10.1158/1535-7163.MCT-09-0115] [Cited by in Crossref: 59] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
33 Wei W, Ji L, Duan W, Zhu J. Circular RNA circ_0081001 knockdown enhances methotrexate sensitivity in osteosarcoma cells by regulating miR-494-3p/TGM2 axis. J Orthop Surg Res 2021;16:50. [PMID: 33435987 DOI: 10.1186/s13018-020-02169-5] [Reference Citation Analysis]
34 Diao ZB, Sun TX, Zong Y, Lin BC, Xia YS. Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res 2020;48:300060520967818. [PMID: 33284712 DOI: 10.1177/0300060520967818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Roundhill EA, Jabri S, Burchill SA. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells. Cancer Letters 2019;453:142-57. [DOI: 10.1016/j.canlet.2019.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
36 Osaki S, Tazawa H, Hasei J, Yamakawa Y, Omori T, Sugiu K, Komatsubara T, Fujiwara T, Sasaki T, Kunisada T, Yoshida A, Urata Y, Kagawa S, Ozaki T, Fujiwara T. Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. Sci Rep 2016;6:28953. [PMID: 27356624 DOI: 10.1038/srep28953] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
37 Liu G, An L, Zhang H, Du P, Sheng Y. Activation of CXCL6/CXCR1/2 Axis Promotes the Growth and Metastasis of Osteosarcoma Cells in vitro and in vivo. Front Pharmacol 2019;10:307. [PMID: 30984000 DOI: 10.3389/fphar.2019.00307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
38 Guo J, Dou D, Zhang T, Wang B. HOTAIR Promotes Cisplatin Resistance of Osteosarcoma Cells by Regulating Cell Proliferation, Invasion, and Apoptosis via miR-106a-5p/STAT3 Axis. Cell Transplant 2020;29:963689720948447. [PMID: 32757663 DOI: 10.1177/0963689720948447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
39 Wen J, Xu Z, Li J, Zhang Y, Fan W, Wang Y, Lu M, Li J. Decreased WWOX expression promotes angiogenesis in osteosarcoma. Oncotarget 2017;8:60917-32. [PMID: 28977834 DOI: 10.18632/oncotarget.17126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
40 Guan M, Wang J, Yang L, Zhao Z, Lu K, Zhao L, Xiao J, Li Z, Shi Z. Targeting osteosarcoma vasculature with peptide obtained by phage display. Contemp Oncol (Pozn) 2014;18:165-70. [PMID: 25520575 DOI: 10.5114/wo.2014.41384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Chen B, Yang JZ, Wang LF, Zhang YJ, Lin XJ. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. BMC Cancer 2015;15:752. [PMID: 26486165 DOI: 10.1186/s12885-015-1735-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
42 Duarte IF, Lamego I, Marques J, Marques MPM, Blaise BJ, Gil AM. Nuclear Magnetic Resonance (NMR) Study of the Effect of Cisplatin on the Metabolic Profile of MG-63 Osteosarcoma Cells. J Proteome Res 2010;9:5877-86. [DOI: 10.1021/pr100635n] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
43 Li G, Li Y, Wang DY. Overexpression of miR-329-3p sensitizes osteosarcoma cells to cisplatin through suppression of glucose metabolism by targeting LDHA. Cell Biol Int 2021;45:766-74. [PMID: 33058436 DOI: 10.1002/cbin.11476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yang D, Xu T, Fan L, Liu K, Li G. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis. J Exp Clin Cancer Res 2020;39:201. [PMID: 32972441 DOI: 10.1186/s13046-020-01670-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Li S, Liu XY, Pan Q, Wu J, Liu ZH, Wang Y, Liu M, Zhang XL. Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells. Viruses 2019;11:E378. [PMID: 31022917 DOI: 10.3390/v11040378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Fan J, Yang X, Bi Z. Acriflavine suppresses the growth of human osteosarcoma cells through apoptosis and autophagy. Tumour Biol 2014;35:9571-6. [PMID: 24961347 DOI: 10.1007/s13277-014-2156-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
47 Sakamoto A, Yamashita M, Hori Y, Okamoto T, Shimizu A, Matsuda S. Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis. Am J Case Rep 2017;18:1130-4. [PMID: 29061956 DOI: 10.12659/ajcr.905637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
48 Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. Cancer Epidemiol 2015;39:182-8. [PMID: 25592234 DOI: 10.1016/j.canep.2014.12.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
49 Liu Q, Song Y, Duan X, Chang Y, Guo J. MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1. Biomed Res Int 2018;2018:9870693. [PMID: 29984257 DOI: 10.1155/2018/9870693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
50 Kun-Peng Z, Chun-Lin Z, Xiao-Long M, Lei Z. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells. J Cell Physiol 2019;234:6927-39. [PMID: 30204936 DOI: 10.1002/jcp.27435] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
51 Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients. OMICS 2015;19:180-5. [PMID: 25748439 DOI: 10.1089/omi.2014.0159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
52 Qi Y, Zhao C, Li H, Zhang B, Tada K, Abe H, Tada M. Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma. Tumour Biol 2016;37:9807-11. [PMID: 26810186 DOI: 10.1007/s13277-016-4876-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Chen Y, Yang Y, Liu S, Zhu S, Jiang H, Ding J. Association between interleukin 8 -251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case-control study. Tumour Biol 2016;37:6191-6. [PMID: 26615418 DOI: 10.1007/s13277-015-4435-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
54 Li WH, Wu HJ, Li YX, Pan HG, Meng T, Wang X. MicroRNA-143 promotes apoptosis of osteosarcoma cells by caspase-3 activation via targeting Bcl-2. Biomed Pharmacother. 2016;80:8-15. [PMID: 27133034 DOI: 10.1016/j.biopha.2016.03.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
55 Bertino JR. Transfer of drug resistance genes into hematopoietic stem cells for marrow protection. Oncologist 2008;13:1036-42. [PMID: 18952565 DOI: 10.1634/theoncologist.2008-0173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Khanna C. Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep 2008;10:350-8. [PMID: 18778562 DOI: 10.1007/s11912-008-0054-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
57 Zhang X, Duan S, Tao S, Huang J, Liu C, Xing S, Ren Z, Lei Z, Li Y, Wei G. Polysaccharides from Dendrobium officinale inhibit proliferation of osteosarcoma cells and enhance cisplatin-induced apoptosis. Journal of Functional Foods 2020;73:104143. [DOI: 10.1016/j.jff.2020.104143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kim Y, Kobayashi E, Kubota D, Suehara Y, Mukaihara K, Akaike K, Ito A, Kaneko K, Chuman H, Kawai A, Kitano S. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance. Oncotarget 2016;7:70832-44. [PMID: 27683125 DOI: 10.18632/oncotarget.12225] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
59 Spugnini EP, Baldi A. Electrochemotherapy in veterinary oncology: from rescue to first line therapy. Methods Mol Biol 2014;1121:247-56. [PMID: 24510829 DOI: 10.1007/978-1-4614-9632-8_22] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
60 Wu J, Liao Q, He H, Zhong D, Yin K. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog 2014;53:440-6. [PMID: 23280703 DOI: 10.1002/mc.21991] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
61 Liu C, Ma M, Zhang J, Gui S, Zhang X, Xue S. Galangin inhibits human osteosarcoma cells growth by inducing transforming growth factor-β1-dependent osteogenic differentiation. Biomed Pharmacother 2017;89:1415-21. [PMID: 28340520 DOI: 10.1016/j.biopha.2017.03.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
62 Yang C, Yang S, Wood KB, Hornicek FJ, Schwab JH, Fondren G, Mankin H, Duan Z. Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression. Apoptosis 2009;14:124-33. [PMID: 19052873 DOI: 10.1007/s10495-008-0282-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
63 Wu S, Du X, Wu M, Du H, Shi X, Zhang T. MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion by targeting catenin-δ1. Gene 2016;584:83-9. [PMID: 26992637 DOI: 10.1016/j.gene.2016.03.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
64 Sabile AA, Arlt MJ, Muff R, Husmann K, Hess D, Bertz J, Langsam B, Aemisegger C, Ziegler U, Born W, Fuchs B. Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice. Biochim Biophys Acta 2013;1832:1173-82. [PMID: 23528710 DOI: 10.1016/j.bbadis.2013.03.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
65 Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 2009;100:1227-33. [PMID: 19486338 DOI: 10.1111/j.1349-7006.2009.01165.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
66 Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenetics and Genomics 2014;24:514-21. [DOI: 10.1097/fpc.0000000000000083] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
67 Zhao Z, Jin G, Yao K, Liu K, Liu F, Chen H, Wang K, Gorja DR, Reddy K, Bode AM, Guo Z, Dong Z. Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma. Mol Carcinog 2019;58:1056-67. [PMID: 30790360 DOI: 10.1002/mc.22993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
68 Yu X, Zhou X, Fu C, Wang Q, Nie T, Zou F, Guo R, Liu H, Zhang B, Dai M. Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway. Oncol Rep 2015;34:1129-36. [PMID: 26165547 DOI: 10.3892/or.2015.4124] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
69 Zhou Q, Deng Z, Zhu Y, Long H, Zhang S, Zhao J. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 2010;27:1239-45. [PMID: 19936974 DOI: 10.1007/s12032-009-9365-y] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
70 Zhou C, Tan W, Lv H, Gao F, Sun J. Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma. Cell Oncol (Dordr) 2016;39:463-71. [PMID: 27376839 DOI: 10.1007/s13402-016-0288-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
71 Liang W, Li C, Li M, Wang D, Zhong Z. MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression. Onco Targets Ther 2019;12:7203-14. [PMID: 31564904 DOI: 10.2147/OTT.S194800] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
72 Bernocchi G, Fanizzi FP, De Pascali SA, Piccolini VM, Gasperini C, Insolia V, Bottone MG. Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System. Toxics 2015;3:224-48. [PMID: 29056659 DOI: 10.3390/toxics3020224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
73 Jiang H, Zeng Z. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma. Biochem Biophys Res Commun 2015;468:255-61. [PMID: 26514724 DOI: 10.1016/j.bbrc.2015.10.119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
74 Luo Z, Liu M, Zhang H, Xia Y. Association of circulating miR-125b and survival in patients with osteosarcoma-A single center experience. J Bone Oncol 2016;5:167-72. [PMID: 28008378 DOI: 10.1016/j.jbo.2016.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
75 Tu B, Zhu J, Liu S, Wang L, Fan Q, Hao Y, Fan C, Tang TT. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Oncotarget 2016;7:48296-308. [PMID: 27340780 DOI: 10.18632/oncotarget.10219] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
76 Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, Duan Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764. [PMID: 20520719 DOI: 10.1371/journal.pone.0010764] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 8.3] [Reference Citation Analysis]
77 Huynh DL, Kwon T, Zhang JJ, Sharma N, Gera M, Ghosh M, Kim N, Kim Cho S, Lee DS, Park YH, Jeong DK. Wogonin suppresses stem cell-like traits of CD133 positive osteosarcoma cell via inhibiting matrix metallopeptidase-9 expression. BMC Complement Altern Med 2017;17:304. [PMID: 28606135 DOI: 10.1186/s12906-017-1788-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
78 Chu Y, Fang Y, Chi J, Li J, Zhang D, Zou Y, Wang Z. Astragalus polysaccharides decrease proliferation, migration, and invasion but increase apoptosis of human osteosarcoma cells by up-regulation of microRNA-133a. Braz J Med Biol Res 2018;51:e7665. [PMID: 30462772 DOI: 10.1590/1414-431X20187665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
79 Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 2013;5:591-616. [PMID: 24216993 DOI: 10.3390/cancers5020591] [Cited by in Crossref: 131] [Cited by in F6Publishing: 124] [Article Influence: 14.6] [Reference Citation Analysis]
80 Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008;12:928-41. [PMID: 18494934 DOI: 10.1111/j.1582-4934.2008.00141.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
81 Wang J, Hu C, Wang J, Shen Y, Bao Q, He F, Wang H, Gong L, Liu Z, Hu F, Liang J, Zhou Q, Wei L, Wen J, Zhang W. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma. J Immunother 2019;42:321-30. [PMID: 31219973 DOI: 10.1097/CJI.0000000000000281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
82 Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, Bacci G, Ferrari S, Scotlandi K, Picci P, Serra M. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 2008;19:1500-8. [PMID: 18385200 DOI: 10.1093/annonc/mdn148] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
83 Park SH, Lee J, Kang MA, Jang KY, Kim JR. Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway. Oncol Lett 2018;15:9687-96. [PMID: 29928344 DOI: 10.3892/ol.2018.8547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
84 Chang J, Wang H, Wang X, Zhao Y, Zhao D, Wang C, Li Y, Yang Z, Lu S, Zeng Q, Zimmerman J, Shi Q, Wang Y, Yang Y. Molecular mechanisms of Polyphyllin I-induced apoptosis and reversal of the epithelial-mesenchymal transition in human osteosarcoma cells. J Ethnopharmacol 2015;170:117-27. [PMID: 25978954 DOI: 10.1016/j.jep.2015.05.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
85 Rastegar F, Gao JL, Shenaq D, Luo Q, Shi Q, Kim SH, Jiang W, Wagner ER, Huang E, Gao Y, Shen J, Yang K, He BC, Chen L, Zuo GW, Luo J, Luo X, Bi Y, Liu X, Li M, Hu N, Wang L, Luther G, Luu HH, Haydon RC, He TC. Lysophosphatidic acid acyltransferase β (LPAATβ) promotes the tumor growth of human osteosarcoma. PLoS One 2010;5:e14182. [PMID: 21152068 DOI: 10.1371/journal.pone.0014182] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
86 Wang YH, Xiong J, Wang SF, Yu Y, Wang B, Chen YX, Shi HF, Qiu Y. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 2010;341:225-33. [PMID: 20376536 DOI: 10.1007/s11010-010-0453-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
87 Fanelli M, Tavanti E, Patrizio MP, Vella S, Fernandez-Ramos A, Magagnoli F, Luppi S, Hattinger CM, Serra M. Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments. Front Oncol 2020;10:331. [PMID: 32211337 DOI: 10.3389/fonc.2020.00331] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
88 Mickymaray S, Alfaiz FA, Paramasivam A, Veeraraghavan VP, Periadurai ND, Surapaneni KM, Niu G. Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway. Saudi J Biol Sci 2021;28:3641-9. [PMID: 34220214 DOI: 10.1016/j.sjbs.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Castro-gamero AM, Borges KS, da Silva Silveira V, Lira RCP, de Paula Gomes Queiroz R, Valera FCP, Scrideli CA, Umezawa K, Tone LG. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anti-Cancer Drugs 2012;23:638-50. [DOI: 10.1097/cad.0b013e328350e835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Zhu B, Ren C, Du K, Zhu H, Ai Y, Kang F, Luo Y, Liu W, Wang L, Xu Y, Jiang X, Zhang Y. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways. Biochem Pharmacol 2019;170:113642. [PMID: 31541631 DOI: 10.1016/j.bcp.2019.113642] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
91 Wang Y, Sun L, Mei Z, Zhang F, He M, Fletcher C, Wang F, Yang J, Bi D, Jiang Y, Liu P. 3D printed biodegradable implants as an individualized drug delivery system for local chemotherapy of osteosarcoma. Materials & Design 2020;186:108336. [DOI: 10.1016/j.matdes.2019.108336] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
92 Zhang Y, Duan G, Feng S. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun 2015;459:367-73. [PMID: 25727016 DOI: 10.1016/j.bbrc.2015.02.101] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
93 Chao L, Liu J, Zhao D. Increased Six1 expression is associated with poor prognosis in patients with osteosarcoma. Oncol Lett 2017;13:2891-6. [PMID: 28521394 DOI: 10.3892/ol.2017.5803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
94 Sun HB, Wang HY, Wu B, Wang ZF, Wang LZ, Li FQ, Wu JD, Zhang LN. The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments. Oncol Lett 2019;18:6385-96. [PMID: 31807162 DOI: 10.3892/ol.2019.11019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523-532. [PMID: 24345772 DOI: 10.1016/j.ctrv.2013.11.006] [Cited by in Crossref: 634] [Cited by in F6Publishing: 633] [Article Influence: 70.4] [Reference Citation Analysis]
96 Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T, Zhang L. Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther 2019;27:518-30. [PMID: 30692017 DOI: 10.1016/j.ymthe.2019.01.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 20.0] [Reference Citation Analysis]
97 Yang C, Hornicek FJ, Wood KB, Schwab JH, Mankin H, Duan Z. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. Cancer Chemother Pharmacol 2009;64:607-14. [DOI: 10.1007/s00280-008-0912-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
98 Duan R, Li C, Wang F, Yangi JC. Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma. Colloids Surf B Biointerfaces 2017;159:880-7. [PMID: 28892872 DOI: 10.1016/j.colsurfb.2017.08.042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
99 Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol JA. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer 2009;8:72. [PMID: 19735553 DOI: 10.1186/1476-4598-8-72] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
100 Fallarini S, Paoletti T, Orsi Battaglini N, Lombardi G. Invariant NKT cells increase drug-induced osteosarcoma cell death. Br J Pharmacol 2012;167:1533-49. [PMID: 22817659 DOI: 10.1111/j.1476-5381.2012.02108.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
101 Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 2014;14:681. [PMID: 25236161 DOI: 10.1186/1471-2407-14-681] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
102 Cui Y, Zhu JJ, Ma CB, Cui K, Wang F, Ni SH, Zhang ZY. Genetic polymorphisms in MMP 2, 3 and 9 genes and the susceptibility of osteosarcoma in a Chinese Han population. Biomarkers 2016;21:160-3. [PMID: 26754027 DOI: 10.3109/1354750X.2015.1118550] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
103 Fu Z, Deng B, Liao Y, Shan L, Yin F, Wang Z, Zeng H, Zuo D, Hua Y, Cai Z. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 2013;13:580. [PMID: 24314238 DOI: 10.1186/1471-2407-13-580] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
104 Ma Y, Zhu B, Liu X, Yu H, Yong L, Liu X, Shao J, Liu Z. Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 2015;34:115. [PMID: 26444270 DOI: 10.1186/s13046-015-0232-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
105 Freeman FE, Burdis R, Mahon OR, Kelly DJ, Artzi N. A Spheroid Model of Early and Late-Stage Osteosarcoma Mimicking the Divergent Relationship between Tumor Elimination and Bone Regeneration. Adv Healthc Mater 2021;:e2101296. [PMID: 34636176 DOI: 10.1002/adhm.202101296] [Reference Citation Analysis]
106 Di Fiore R, Fanale D, Drago-ferrante R, Chiaradonna F, Giuliano M, De Blasio A, Amodeo V, Corsini LR, Bazan V, Tesoriere G, Vento R, Russo A. Genetic and molecular characterization of the human Osteosarcoma 3AB-OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness. J Cell Physiol 2013;228:1189-201. [DOI: 10.1002/jcp.24272] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
107 Ma L, Xu Y, Xu X. Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models. Biochem Biophys Res Commun 2020;529:622-8. [PMID: 32736683 DOI: 10.1016/j.bbrc.2020.06.082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zocchi L, Wu SC, Wu J, Hayama KL, Benavente CA. The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget 2018;9:23505-18. [PMID: 29805751 DOI: 10.18632/oncotarget.25239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
109 Li YY, Wu H, Dong YG, Lin BO, Xu G, Ma YB. Application of eupatilin in the treatment of osteosarcoma. Oncol Lett 2015;10:2505-10. [PMID: 26622880 DOI: 10.3892/ol.2015.3563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
110 Du GY, He SW, Zhang L, Sun CX, Mi LD, Sun ZG. Hesperidin exhibits in vitro and in vivo antitumor effects in human osteosarcoma MG-63 cells and xenograft mice models via inhibition of cell migration and invasion, cell cycle arrest and induction of mitochondrial-mediated apoptosis. Oncol Lett 2018;16:6299-306. [PMID: 30405765 DOI: 10.3892/ol.2018.9439] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
111 He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014;7:1352-62. [PMID: 24765137 DOI: 10.3892/ol.2014.1935] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 17.5] [Reference Citation Analysis]
112 Kuo TT, Wang CH, Wang JY, Chiou HJ, Fan CH, Yeh CK. Concurrent Osteosarcoma Theranostic Strategy Using Contrast-Enhanced Ultrasound and Drug-Loaded Bubbles. Pharmaceutics 2019;11:E223. [PMID: 31071997 DOI: 10.3390/pharmaceutics11050223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
113 Zhang D, Pan X, Ohno S, Osuga T, Sawada S, Sato K. No effects of pulsed electromagnetic fields on expression of cell adhesion molecules (integrin, CD44) and matrix metalloproteinase-2/9 in osteosarcoma cell lines. Bioelectromagnetics 2011;32:463-73. [DOI: 10.1002/bem.20647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
114 Jimmy R, Stern C, Lisy K, White S. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review. JBI Database of Systematic Reviews and Implementation Reports 2017;15:2113-52. [DOI: 10.11124/jbisrir-2016-003105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
115 Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008;10:315-27. [PMID: 18754698 DOI: 10.2165/00148581-200810050-00005] [Cited by in Crossref: 179] [Cited by in F6Publishing: 160] [Article Influence: 12.8] [Reference Citation Analysis]
116 Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, Yang C, Mankin H, Hornicek FJ. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 2010;293:220-9. [PMID: 20144850 DOI: 10.1016/j.canlet.2010.01.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
117 Gui K, Zhang X, Chen F, Ge Z, Zhang S, Qi X, Sun J, Yu Z. Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells. Biomed Pharmacother 2019;111:751-64. [PMID: 30612000 DOI: 10.1016/j.biopha.2018.11.118] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
118 Li Z, Wu S, Lv S, Wang H, Wang Y, Guo Q. Suppression of liver receptor homolog-1 by microRNA-451 represses the proliferation of osteosarcoma cells. Biochem Biophys Res Commun 2015;461:450-5. [PMID: 25869073 DOI: 10.1016/j.bbrc.2015.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
119 Lee YH, Yang HW, Yang LC, Lu MY, Tsai LL, Yang SF, Huang YF, Chou MY, Yu CC, Hu FW. DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells. Oncol Lett 2017;14:171-9. [PMID: 28693150 DOI: 10.3892/ol.2017.6132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
120 Chen H, Chen F, Wang X, Gou S. Multifunctional Pt(iv) complexes containing a glutathione S-transferase inhibitor lead to enhancing anticancer activity and preventing metastasis of osteosarcoma cells. Metallomics 2019;11:317-26. [PMID: 30560252 DOI: 10.1039/c8mt00296g] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Mukherjee S, Dash S, Lohitesh K, Chowdhury R. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. PLoS One 2017;12:e0179203. [PMID: 28598976 DOI: 10.1371/journal.pone.0179203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
122 Fernandes I, Melo-Alvim C, Lopes-Brás R, Esperança-Martins M, Costa L. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments. Int J Mol Sci 2021;22:E813. [PMID: 33467481 DOI: 10.3390/ijms22020813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
123 Wei D, Li C, Ye J, Xiang F, Xu Y, Liu J. Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma. Cell Biol Int 2021;45:382-93. [PMID: 33135822 DOI: 10.1002/cbin.11494] [Reference Citation Analysis]
124 Otoukesh B, Abbasi M, Gorgani HO, Farahini H, Moghtadaei M, Boddouhi B, Kaghazian P, Hosseinzadeh S, Alaee A. MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma. Cancer Cell Int 2020;20:254. [PMID: 32565738 DOI: 10.1186/s12935-020-01342-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
125 Asnafi AA, Behzad MM, Ghanavat M, Shahjahani M, Saki N. Singe nucleotide polymorphisms in osteosarcoma: Pathogenic effect and prognostic significance. Experimental and Molecular Pathology 2019;106:63-77. [DOI: 10.1016/j.yexmp.2018.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
126 Li J, Liu S, Wang W, Zhang K, Liu Z, Zhang C, Chen S, Wu S. ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol 2014;35:10129-36. [PMID: 25023406 DOI: 10.1007/s13277-014-2322-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
127 Das B, Jain N, Mallick B. piR‐39980 promotes cell proliferation, migration and invasion, and inhibits apoptosis via repression of SERPINB1 in human osteosarcoma. Biol Cell 2020;112:73-91. [DOI: 10.1111/boc.201900063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
128 Zheng SE, Xiong S, Lin F, Qiao GL, Feng T, Shen Z, Min DL, Zhang CL, Yao Y. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin 2012;33:832-8. [PMID: 22580740 DOI: 10.1038/aps.2012.20] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
129 Cui Y, Zhu JJ, Ma CB, Cui K, Wang F, Ni SH, Zhang ZY. Interleukin 10 gene -1082A/G polymorphism is associated with osteosarcoma risk and poor outcomes in the Chinese population. Tumour Biol 2016;37:4517-22. [PMID: 26503210 DOI: 10.1007/s13277-015-4238-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
130 Li Z, Wang L, Luo N, Zhao Y, Li J, Chen Q, Tian Y. Metformin inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the phosphorylation of Akt. Oncol Lett 2018;15:7948-54. [PMID: 29725482 DOI: 10.3892/ol.2018.8297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
131 Caronia D, Patiño-Garcia A, Peréz-Martínez A, Pita G, Moreno LT, Zalacain-Díez M, Molina B, Colmenero I, Sierrasesúmaga L, Benítez J, Gonzalez-Neira A. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One 2011;6:e26091. [PMID: 22016816 DOI: 10.1371/journal.pone.0026091] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
132 Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Cancer Biol Ther 2015;16:602-9. [PMID: 25869769 DOI: 10.1080/15384047.2015.1017155] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
133 Serra M, Hattinger CM. The pharmacogenomics of osteosarcoma. Pharmacogenomics J 2017;17:11-20. [PMID: 27241064 DOI: 10.1038/tpj.2016.45] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
134 Ni K, Yang L, Wan C, Xia Y, Kong L. Flavonostilbenes from Sophora alopecuroides L. as multidrug resistance associated protein 1 (MRP1) inhibitors. Nat Prod Res 2014;28:2195-8. [PMID: 24956120 DOI: 10.1080/14786419.2014.930856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
135 Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, Duan Z. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 2012;118:2905-14. [PMID: 22006429 DOI: 10.1002/cncr.26617] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
136 Zhou Y, Liu B, Wang M, Ni J. Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. Pediatr Blood Cancer 2014;61:612-7. [PMID: 24123836 DOI: 10.1002/pbc.24790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
137 Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel) 2021;13:683. [PMID: 33567616 DOI: 10.3390/cancers13040683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
138 Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, Serra M. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 2009;48:289-309. [PMID: 19105235 DOI: 10.1002/gcc.20640] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
139 Xu D, Zhu H, Wang C, Zhao W, Liu G, Bao G, Cui D, Fan J, Wang F, Jin H, Cui Z. SphK2 over-expression promotes osteosarcoma cell growth. Oncotarget 2017;8:105525-35. [PMID: 29285269 DOI: 10.18632/oncotarget.22314] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
140 Zhao X, Ma S, Liu N, Liu J, Wang W. A polysaccharide from Trametes robiniophila Murrill induces apoptosis through intrinsic mitochondrial pathway in human osteosarcoma (U-2 OS) cells. Tumor Biol 2015;36:5255-63. [DOI: 10.1007/s13277-015-3185-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
141 Wang Y, Zeng L, Liang C, Zan R, Ji W, Zhang Z, Wei Y, Tu S, Dong Y. Integrated analysis of transcriptome-wide m6A methylome of osteosarcoma stem cells enriched by chemotherapy. Epigenomics 2019;11:1693-715. [PMID: 31650864 DOI: 10.2217/epi-2019-0262] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
142 Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008;3:228-31. [PMID: 18782081 DOI: 10.2174/157488708785700267] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
143 Gill KS, Fernandes P, Bird B, Soden DM, Forde PF. Combination of electroporation delivered metabolic modulators with low-dose chemotherapy in osteosarcoma. Oncotarget 2018;9:31473-89. [PMID: 30140384 DOI: 10.18632/oncotarget.25843] [Reference Citation Analysis]
144 Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. BMC Med Genet 2018;19:112. [PMID: 29980176 DOI: 10.1186/s12881-018-0627-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
145 Li QC, Xu H, Wang X, Wang T, Wu J. miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. Cancer Biomark 2017;21:135-44. [PMID: 29060932 DOI: 10.3233/CBM-170452] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
146 Dieudonné FX, Marion A, Marie PJ, Modrowski D. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice. J Bone Miner Res 2012;27:2118-29. [PMID: 22550000 DOI: 10.1002/jbmr.1650] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
147 Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2011;129:680-690. [PMID: 20949564 DOI: 10.1002/ijc.25715] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 8.4] [Reference Citation Analysis]
148 Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Disruption of IGF‑1R signaling by a novel quinazoline derivative, HMJ‑30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U‑2 OS cells. Int J Oncol 2018;52:1465-78. [PMID: 29568964 DOI: 10.3892/ijo.2018.4325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
149 Zhou Y, Zang X, Huang Z, Zhang C. TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett 2013;5:857-61. [PMID: 23426781 DOI: 10.3892/ol.2013.1111] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
150 Cheng L, Wei X, Zhao K, Wu F, Lu W, Tong S, Yu G. The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma. Tumor Biol 2016;37:14961-7. [DOI: 10.1007/s13277-016-5384-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
151 Feng H, Zhang Q, Zhao Y, Zhao L, Shan B. Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells. Aging (Albany NY) 2020;12:6340-51. [PMID: 32289750 DOI: 10.18632/aging.103027] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Sun Y, Wang F, Wang L, Jiao Z, Fang J, Li J. MicroRNA-433 regulates apoptosis by targeting PDCD4 in human osteosarcoma cells. Oncol Lett 2017;14:2353-8. [PMID: 28781674 DOI: 10.3892/ol.2017.6441] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
153 Wang LF, Zhou Y, Xu YM, Qiu XC, Zhou BG, Wang F, Long H, Chen X, Yang TT, Ma BA, Fan QY, Yang AG. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009;27:774-80. [PMID: 19488908 DOI: 10.1080/07357900802427935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
154 Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 2011;20:13-9. [PMID: 19836228 DOI: 10.1016/j.suronc.2009.09.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
155 Chang Z, Huo L, Li K, Wu Y, Hu Z. Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. ScientificWorldJournal 2014;2014:794756. [PMID: 25013866 DOI: 10.1155/2014/794756] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
156 Liu L, Wang S. Long Non-Coding RNA OIP5-AS1 Knockdown Enhances CDDP Sensitivity in Osteosarcoma via miR-377-3p/FOSL2 Axis. Onco Targets Ther 2020;13:3853-66. [PMID: 32440152 DOI: 10.2147/OTT.S232918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
157 Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci 2020;21:E6885. [PMID: 32961800 DOI: 10.3390/ijms21186885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
158 Xiong Q, Wang X, Wang L, Huang Y, Tian X, Fan Y, Lin CY. BMP-2 inhibits lung metastasis of osteosarcoma: an early investigation using an orthotopic model. Onco Targets Ther 2018;11:7543-53. [PMID: 30464502 DOI: 10.2147/OTT.S176724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
159 Chen J, Song Y, Yang J, Gong L, Zhao P, Zhang Y, Su H. The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration. Mol Cell Biochem 2013;384:269-77. [PMID: 24037310 DOI: 10.1007/s11010-013-1807-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
160 Sharma H, Niveditha D, Chowdhury R, Mukherjee S, Chowdhury S. A genome-wide expression profile of noncoding RNAs in human osteosarcoma cells as they acquire resistance to cisplatin. Discov Onc 2021;12. [DOI: 10.1007/s12672-021-00441-6] [Reference Citation Analysis]
161 Gougelet A, Perez J, Pissaloux D, Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY, Alberti L. miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma 2011;2011:460650. [PMID: 21437224 DOI: 10.1155/2011/460650] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
162 Cao S, Jiang L, Shen L, Xiong Z. Role of microRNA-92a in metastasis of osteosarcoma cells in vivo and in vitro by inhibiting expression of TCF21 with the transmission of bone marrow derived mesenchymal stem cells. Cancer Cell Int 2019;19:31. [PMID: 30804710 DOI: 10.1186/s12935-019-0741-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
163 Zhou J, Liu Q, Qian R, Liu S, Hu W, Liu Z. Paeonol antagonizes oncogenesis of osteosarcoma by inhibiting the function of TLR4/MAPK/NF-κB pathway. Acta Histochem 2020;122:151455. [PMID: 31587886 DOI: 10.1016/j.acthis.2019.151455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
164 Kang C, Zhao J, Wang Y, Yang C, Chen J, Zhi L. Relationship of common variants in Interleukin 33 gene with susceptibility and prognosis of osteosarcoma in Han Chinese population. J Cancer 2019;10:1138-44. [PMID: 30854122 DOI: 10.7150/jca.29086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
165 Zhou X, Wu J, Duan C, Liu Y. Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. J Immunol Res 2020;2020:7890985. [PMID: 33062726 DOI: 10.1155/2020/7890985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Wang X, Zheng H, Shou T, Tang C, Miao K, Wang P. Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials. J Orthop Surg Res 2017;12:52. [PMID: 28356114 DOI: 10.1186/s13018-017-0544-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
167 Zhang B, Zhang Y, Li R, Li J, Lu X, Zhang Y. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis. J Orthop Surg Res 2020;15:51. [PMID: 32054494 DOI: 10.1186/s13018-020-1576-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
168 Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr 2015;3:69. [PMID: 26380245 DOI: 10.3389/fped.2015.00069] [Cited by in Crossref: 90] [Cited by in F6Publishing: 99] [Article Influence: 12.9] [Reference Citation Analysis]
169 Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br J Cancer 2013;109:2607-18. [PMID: 24129234 DOI: 10.1038/bjc.2013.643] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
170 Jiang C, Fang X, Zhang H, Wang X, Li M, Jiang W, Tian F, Zhu L, Bian Z. Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro. Tumour Biol 2017;39:1010428317697556. [PMID: 28381158 DOI: 10.1177/1010428317697556] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
171 Wan B, Hu H, Wang R, Liu W, Chen D. Therapeutic Potential of Circular RNAs in Osteosarcoma. Front Oncol 2020;10:370. [PMID: 32351876 DOI: 10.3389/fonc.2020.00370] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
172 Moon MH, Jeong JK, Seo JS, Seol JW, Lee YJ, Xue M, Jackson CJ, Park SY. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med 2011;43:138-45. [PMID: 21297379 DOI: 10.3858/emm.2011.43.3.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
173 Chiang YH, Wu SH, Kuo YC, Chen HF, Chiou A, Lee OK. Raman spectroscopy for grading of live osteosarcoma cells. Stem Cell Res Ther 2015;6:81. [PMID: 25928011 DOI: 10.1186/s13287-015-0074-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
174 Lenna S, Bellotti C, Duchi S, Martella E, Columbaro M, Dozza B, Ballestri M, Guerrini A, Sotgiu G, Frisoni T, Cevolani L, Varchi G, Ferrari M, Donati DM, Lucarelli E. Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model. J Exp Clin Cancer Res. 2020;39:40. [PMID: 32087737 DOI: 10.1186/s13046-020-01548-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
175 Pu Y, Tan Y, Zang C, Zhao F, Cai C, Kong L, Deng H, Chao F, Xia R, Xie M, Ge F, Pan Y, Cai S, Huang D. LAMTOR5-AS1 regulates chemotherapy-induced oxidative stress by controlling the expression level and transcriptional activity of NRF2 in osteosarcoma cells. Cell Death Dis 2021;12:1125. [PMID: 34862368 DOI: 10.1038/s41419-021-04413-0] [Reference Citation Analysis]
176 Mittal N, Kent PM, Ording J. Metastatic and recurrent bone primary bone cancers. Curr Probl Cancer 2013;37:215-24. [PMID: 24238587 DOI: 10.1016/j.currproblcancer.2013.07.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
177 Ng AJ, Mutsaers AJ, Baker EK, Walkley CR. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2012;2:19. [PMID: 23036272 DOI: 10.1186/2045-3329-2-19] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
178 Yu S, Qin X, Chen T, Zhou L, Xu X, Feng J. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anticancer Drugs 2017;28:852-60. [PMID: 28723865 DOI: 10.1097/CAD.0000000000000524] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
179 Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett 2017;396:66-75. [PMID: 28323030 DOI: 10.1016/j.canlet.2017.03.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 19.8] [Reference Citation Analysis]
180 Ai J, Liao W, Ren Z. Enhanced anticancer effect of copper-loaded chitosan nanoparticles against osteosarcoma. RSC Adv 2017;7:15971-7. [DOI: 10.1039/c6ra21648j] [Cited by in Crossref: 17] [Article Influence: 3.4] [Reference Citation Analysis]
181 Ma J, Niu M, Yang W, Zang L, Xi Y. Role of relaxin-2 in human primary osteosarcoma. Cancer Cell Int 2013;13:59. [PMID: 23758748 DOI: 10.1186/1475-2867-13-59] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
182 Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin K, Roh JK, Rha SY. Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. Oncology 2011;80:107-17. [DOI: 10.1159/000327216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
183 Avril T, Vauléon E, Chevet E. Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis 2017;6:e373. [PMID: 28846078 DOI: 10.1038/oncsis.2017.72] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 21.2] [Reference Citation Analysis]
184 Sero V, Tavanti E, Vella S, Hattinger CM, Fanelli M, Michelacci F, Versteeg R, Valsasina B, Gudeman B, Picci P, Serra M. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs 2014;32:1167-80. [DOI: 10.1007/s10637-014-0158-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
185 Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 2014;33:12. [PMID: 24468065 DOI: 10.1186/1756-9966-33-12] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 10.4] [Reference Citation Analysis]
186 Di Fiore R, Marcatti M, Drago-Ferrante R, D'Anneo A, Giuliano M, Carlisi D, De Blasio A, Querques F, Pastore L, Tesoriere G, Vento R. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells. Bone 2014;60:198-212. [PMID: 24373920 DOI: 10.1016/j.bone.2013.12.021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
187 Caronia D, Patiño-garcía A, Milne RL, Zalacain-díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-ariznabarreta L, Benítez J, González-neira A. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009;9:347-53. [DOI: 10.1038/tpj.2009.19] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
188 Guan H, Xu H, Chen J, Wu W, Chen D, Chen Y, Sun J. Circ_0001721 enhances doxorubicin resistance and promotes tumorigenesis in osteosarcoma through miR-758/TCF4 axis. Cancer Cell Int 2021;21:336. [PMID: 34215252 DOI: 10.1186/s12935-021-02016-5] [Reference Citation Analysis]
189 Gao Y, Liao Y, Shen JK, Feng Y, Choy E, Cote G, Harmon D, Mankin HJ, Hornicek FJ, Duan Z. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray: P-GLYCOPROTEIN IN OSTEOSARCOMA. J Orthop Res 2016;34:1606-12. [DOI: 10.1002/jor.23173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
190 Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TJ, Schellens JH. Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report. Tumori 2011;97:109-14. [DOI: 10.1177/030089161109700119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
191 Wang L, Jin F, Qin A, Hao Y, Dong Y, Ge S, Dai K. Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family. Mol Cancer 2014;13:139. [PMID: 24894297 DOI: 10.1186/1476-4598-13-139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
192 Bernocchi G, Bottone MG, Piccolini VM, Dal Bo V, Santin G, De Pascali SA, Migoni D, Fanizzi FP. Developing central nervous system and vulnerability to platinum compounds. Chemother Res Pract 2011;2011:315418. [PMID: 22312552 DOI: 10.1155/2011/315418] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
193 Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, Serra M. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 2015;20:495-514. [PMID: 26021401 DOI: 10.1517/14728214.2015.1051965] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
194 Yin JQ, Wen L, Wu LC, Gao ZH, Huang G, Wang J, Zou CY, Tan PX, Yong BC, Jia Q, Shen JN. The glycogen synthase kinase-3β/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells. Toxicol Lett 2013;218:129-36. [PMID: 23164673 DOI: 10.1016/j.toxlet.2012.11.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
195 Yong B, Tan P, Yin J, Zou C, Xie X, Wang J, Huang G, Wang Q, Shen J. Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma. World J Surg Oncol 2012;10:191. [PMID: 22985081 DOI: 10.1186/1477-7819-10-191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
196 Jiang C, He C, Wu Z, Li F, Xiao J. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling. Biochem Biophys Res Commun 2018;502:382-8. [PMID: 29842882 DOI: 10.1016/j.bbrc.2018.05.176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
197 Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010;15:615-34. [PMID: 20690888 DOI: 10.1517/14728214.2010.505603] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
198 Yang TM, Qi SN, Zhao N, Yang YJ, Yuan HQ, Zhang B, Jin S. Induction of apoptosis through caspase-independent or caspase-9-dependent pathway in mouse and human osteosarcoma cells by a new nitroxyl spin-labeled derivative of podophyllotoxin. Apoptosis 2013;18:727-38. [PMID: 23430060 DOI: 10.1007/s10495-013-0819-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
199 Xu Q, Li ZX, Peng HQ, Sun ZW, Cheng RL, Ye ZM, Li WX. Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. J Zhejiang Univ Sci B 2011;12:247-55. [PMID: 21462379 DOI: 10.1631/jzus.B1000373] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
200 Nemcakova I, Jirka I, Doubkova M, Bacakova L. Heat treatment dependent cytotoxicity of silicalite-1 films deposited on Ti-6Al-4V alloy evaluated by bone-derived cells. Sci Rep 2020;10:9456. [PMID: 32528137 DOI: 10.1038/s41598-020-66228-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Lin CC, Chuang YJ, Yu CC, Yang JS, Lu CC, Chiang JH, Lin JP, Tang NY, Huang AC, Chung JG. Apigenin induces apoptosis through mitochondrial dysfunction in U-2 OS human osteosarcoma cells and inhibits osteosarcoma xenograft tumor growth in vivo. J Agric Food Chem 2012;60:11395-402. [PMID: 23066961 DOI: 10.1021/jf303446x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
202 Susa M, Iyer AK, Ryu K, Hornicek FJ, Mankin H, Amiji MM, Duan Z. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer 2009;9:399. [PMID: 19917123 DOI: 10.1186/1471-2407-9-399] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 8.0] [Reference Citation Analysis]
203 Zandi Z, Kashani B, Alishahi Z, Pourbagheri-Sigaroodi A, Esmaeili F, Ghaffari SH, Bashash D, Momeny M. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance. J Cancer Res Clin Oncol 2022;148:57-70. [PMID: 34981193 DOI: 10.1007/s00432-021-03874-2] [Reference Citation Analysis]
204 Fageria L, Pareek V, Dilip RV, Bhargava A, Pasha SS, Laskar IR, Saini H, Dash S, Chowdhury R, Panwar J. Biosynthesized Protein-Capped Silver Nanoparticles Induce ROS-Dependent Proapoptotic Signals and Prosurvival Autophagy in Cancer Cells. ACS Omega 2017;2:1489-504. [PMID: 30023637 DOI: 10.1021/acsomega.7b00045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
205 Koski C, Sarkar N, Bose S. Cytotoxic and osteogenic effects of crocin and bicarbonate from calcium phosphates for potential chemopreventative and anti-inflammatory applications in vitro and in vivo. J Mater Chem B 2020;8:2048-62. [PMID: 32064472 DOI: 10.1039/c9tb01462d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
206 Xu Z, He W, Ke T, Zhang Y, Zhang G. DHRS12 inhibits the proliferation and metastasis of osteosarcoma via Wnt3a/β-catenin pathway. Future Oncol 2020;16:665-74. [PMID: 32250163 DOI: 10.2217/fon-2019-0432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
207 Bravo D, Shogren KL, Zuo D, Wagner ER, Sarkar G, Yaszemski MJ, Maran A. 2-Methoxyestradiol-Mediated Induction of Frzb Contributes to Cell Death and Autophagy in MG63 Osteosarcoma Cells. J Cell Biochem 2017;118:1497-504. [PMID: 27883247 DOI: 10.1002/jcb.25809] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
208 Huang G, Yong BC, Xu MH, Li JC, Guo HH, Shen JN. Analysis of Selenium Levels in Osteosarcoma Patients and the Effects of Se-Methylselenocysteine on Osteosarcoma Cells In Vitro. Nutr Cancer 2015;67:847-56. [PMID: 26121331 DOI: 10.1080/01635581.2015.1042548] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
209 Chang I, Chiang T, Lo C, Lai Y, Yue C, Liu J, Hsu L, Lee C. Anemone altaica Induces Apoptosis in Human Osteosarcoma Cells. Am J Chin Med 2015;43:1031-42. [DOI: 10.1142/s0192415x15500597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
210 Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Kline Z, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. Biomed Pharmacother 2019;118:109356. [PMID: 31545293 DOI: 10.1016/j.biopha.2019.109356] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
211 Ding L, Wang C, Cui Y, Han X, Zhou Y, Bai J, Li R. S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells. Int J Oncol 2018;52:1841-52. [PMID: 29620168 DOI: 10.3892/ijo.2018.4345] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
212 Prasad SR, Kumar TSS, Jayakrishnan A. Nanocarrier-based drug delivery systems for bone cancer therapy: a review. Biomed Mater 2021;16. [PMID: 33853043 DOI: 10.1088/1748-605X/abf7d5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Chiu YJ, Hour MJ, Lu CC, Chung JG, Kuo SC, Huang WW, Chen HJ, Jin YA, Yang JS. Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway. J Orthop Res 2011;29:1448-56. [PMID: 21425328 DOI: 10.1002/jor.21398] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
214 Pan Q, Sun L, Zheng D, Li N, Shi H, Song J, Shao G, Xu G. MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2. Biomed Res Int 2018;2018:1769040. [PMID: 30175116 DOI: 10.1155/2018/1769040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
215 Cho Y, Jung GH, Chung SH, Kim JY, Choi Y, Kim JD. Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution. Clin Orthop Surg 2011;3:48-54. [PMID: 21369478 DOI: 10.4055/cios.2011.3.1.48] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
216 Monterde-Cruz L, Ramírez-Salazar EG, Rico-Martínez G, Linares-González LM, Guzmán-González R, Delgado-Cedillo E, Estrada-Villaseñor E, Valdés-Flores M, Velázquez-Cruz R, Hidalgo-Bravo A. MicroRNA expression in relation with clinical evolution of osteosarcoma. Pathol Res Pract 2020;216:153038. [PMID: 32703501 DOI: 10.1016/j.prp.2020.153038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Yao C, Wu S, Li D, Ding H, Wang Z, Yang Y, Yan S, Gu Z. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Mol Oncol 2012;6:392-404. [PMID: 22583777 DOI: 10.1016/j.molonc.2012.04.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
218 Duchi S, Sotgiu G, Lucarelli E, Ballestri M, Dozza B, Santi S, Guerrini A, Dambruoso P, Giannini S, Donati D, Ferroni C, Varchi G. Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. J Control Release 2013;168:225-37. [PMID: 23524189 DOI: 10.1016/j.jconrel.2013.03.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
219 Gao Z, Zhao GS, Lv Y, Peng D, Tang X, Song H, Guo QN. Anoikis‑resistant human osteosarcoma cells display significant angiogenesis by activating the Src kinase‑mediated MAPK pathway. Oncol Rep 2019;41:235-45. [PMID: 30542722 DOI: 10.3892/or.2018.6827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
220 Ye S, Shen J, Choy E, Yang C, Mankin H, Hornicek F, Duan Z. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. Cancer Chemother Pharmacol 2016;77:349-56. [PMID: 26698867 DOI: 10.1007/s00280-015-2944-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
221 Zhu Z, Tang J, Wang J, Duan G, Zhou L, Zhou X. MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells. PLoS One 2016;11:e0150026. [PMID: 27019355 DOI: 10.1371/journal.pone.0150026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
222 Song WS, Jeon DG, Kong CB, Cho WH, Koh JS, Lee JA, Yoo JY, Jung ST, Shin DS, Lee SY. Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma. Ann Surg Oncol 2011;18:1710-6. [PMID: 21222166 DOI: 10.1245/s10434-010-1536-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
223 Lin Z, Song D, Wei H, Yang X, Liu T, Yan W, Xiao J. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma. J Cancer Res Clin Oncol 2016;142:239-46. [DOI: 10.1007/s00432-015-2028-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
224 Hattinger CM, Michelacci F, Sella F, Magagnoli G, Benini S, Gambarotti M, Palmerini E, Picci P, Serra M, Ferrari S. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology 2015;67:338-47. [PMID: 25600168 DOI: 10.1111/his.12653] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
225 Guo J, Kong LM, Peng AF, Long XH, Zhou Y, Shu Y. Transcription factor NF‑YA promotes a malignant phenotype by upregulating fatty acid synthase expression. Mol Med Rep 2016;14:5007-14. [PMID: 27840951 DOI: 10.3892/mmr.2016.5897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
226 Endo-Munoz L, Cumming A, Sommerville S, Dickinson I, Saunders NA. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br J Cancer 2010;103:73-81. [PMID: 20551950 DOI: 10.1038/sj.bjc.6605723] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
227 Wang H, Yang Q, Fu Z, Zuo D, Hua Y, Cai Z. ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas. Cancer Invest 2014;32:533-42. [PMID: 25347730 DOI: 10.3109/07357907.2014.964409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
228 Zhu YR, Xu Y, Fang JF, Zhou F, Deng XW, Zhang YQ. Bufotalin-induced apoptosis in osteoblastoma cells is associated with endoplasmic reticulum stress activation. Biochem Biophys Res Commun 2014;451:112-8. [PMID: 25068992 DOI: 10.1016/j.bbrc.2014.07.077] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
229 Nada OH, Ahmed NS, Abou Gabal HH. Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol 2014;9:72. [PMID: 24667142 DOI: 10.1186/1746-1596-9-72] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
230 Santos A, Domingues C, Jarak I, Veiga F, Figueiras A. Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. Eur J Pharm Biopharm 2021:S0939-6411(21)00352-0. [PMID: 34896571 DOI: 10.1016/j.ejpb.2021.12.003] [Reference Citation Analysis]
231 Wang TK, Lin YM, Lo CM, Tang CH, Teng CL, Chao WT, Wu MH, Liu CS, Hsieh M. Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells. Tumour Biol 2016;37:7989-8005. [PMID: 26711783 DOI: 10.1007/s13277-015-4661-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
232 Palmini G, Zonefrati R, Mavilia C, Aldinucci A, Luzi E, Marini F, Franchi A, Capanna R, Tanini A, Brandi ML. Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma. J Vis Exp 2016. [PMID: 27768062 DOI: 10.3791/53884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
233 Yu W, Ye M, Zhu J, Wang Y, Liang C, Tang J, Tao H, Shen Y. Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma. Nanomedicine 2018;14:1099-110. [PMID: 29462663 DOI: 10.1016/j.nano.2018.02.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
234 Yang Z, Yu S, Li D, Gong Y, Zang J, Liu J, Chen X. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. Colloids Surf B Biointerfaces 2018;172:387-94. [PMID: 30193198 DOI: 10.1016/j.colsurfb.2018.08.048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
235 Wang SQ, Zhang Q, Sun C, Liu GY. Ifosfamide-loaded lipid-core-nanocapsules to increase the anticancer efficacy in MG63 osteosarcoma cells. Saudi J Biol Sci 2018;25:1140-5. [PMID: 30174514 DOI: 10.1016/j.sjbs.2016.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
236 Huang Z, Huang L, Liu L, Wang L, Lin W, Zhu X, Su W, Lv C. Knockdown of microRNA-203 reduces cisplatin chemo-sensitivity to osteosarcoma cell lines MG63 and U2OS in vitro by targeting RUNX2. J Chemother 2021;33:328-41. [PMID: 33764270 DOI: 10.1080/1120009X.2021.1899441] [Reference Citation Analysis]
237 Gazouli I, Kyriazoglou A, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, Chatzidakis I, Kavourakis G, Economopoulou P, Kontogeorgakos V, Papagelopoulos P, Psyrri A. Systematic Review of Recurrent Osteosarcoma Systemic Therapy. Cancers (Basel) 2021;13:1757. [PMID: 33917001 DOI: 10.3390/cancers13081757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]